

REPORT CLASSIFICATION	✓	CATEGORY OF PAPER	✓
Official		Proposes specific action	
Official: Sensitive Commercial		Provides assurance	✓
Official: Sensitive Personal		For information only	

BOARD	
26 September 2023	
Report Title:	Finance, Performance and Investment (FPI) Committee Approved Minutes
Purpose of report	
To provide the Board with an overview of the key points and approved minutes from the FPI Committee meeting held on 6 July and 3 August 2023.	
Key points	
<p>The Finance, Performance and Investment Committee, chaired by Jon Rush, Non-Executive member of the Board, met on 6 July and 3 August 2023.</p> <p>The key points to bring to Board's attention from the meetings are set out below.</p> <ul style="list-style-type: none"> • ICB financial performance update, which is the regular monthly report that Committee members receive for information and assurance. • ICB performance position update which is the regular monthly report that Committee members receive for information and assurance. • Elective Funding Recovery (ERF) Approach 2023/24, request to approve the proposed allocation model for ERF. • Business As Usual (BAU) Capital Plan, request to approve the split of the BAU capital fair share allocation between digital and estates. • Risk Management report, a quarterly report that Committee members receive for discussion and assurance. <p>The Committee met on 7 September and the confirmed minutes will come to the November Board meeting.</p>	
Risks and issues	
<p>The Committee discussed and noted a number of risks, including:</p> <ul style="list-style-type: none"> • There are risks with the ERF proposed approach and financial activity plans. • Risk for BAU capital that if in-year slippage from national or regional funding is not available some of the larger Estate capital schemes will be delayed until 2024/25 • 2022/23 financial position across the ICS included significant non-recurring benefits, with significant underlying financial pressures which present a risk to the 2023/24 position 	

Item: 9.2.3

- Risk of a cost impact between £8-10m to the ICB 30% running costs reduction requirement was highlighted.
- Newcastle upon Tyne Hospitals FT (NuTHFT) remains in Tier 1 for elective care referral to treat 18 week standard and were unable to provide a trajectory to eliminate the 65 week wait standard. A comprehensive action plan is in place.
- Accident and Emergency (A&E) 4 hour waiting time which was slightly below system plan at 77.1%

Assurances

Assurance was received around the following areas:

- The financial position of both the ICB and the wider ICS will continue to be reviewed in detail on a monthly basis
- Work is progressing on development of a medium-term financial plan for the ICS, incorporating a financial recovery plan.
- Assurances are being received from each provider trust around the implementation / review of relevant financial controls.
- Oversight framework being implemented across North East and North Cumbria.
- The ERF working group will continue to meet to ensure any residual issues with monitoring and transacting the proposal can be addressed.

Recommendation/action required

The Board is asked to receive the confirmed minutes of 6 July and 3 August 2023 for assurance purposes.

Acronyms and abbreviations explained

ICB – Integrated Care Board
ICS – Integrated Care System

Sponsor/approving executive director	Jon Rush, Independent Non Executive Member and Chair of Committee
---	---

Report author	Jen Lawson, Head of Governance
----------------------	--------------------------------

Link to ICB corporate aims (please tick all that apply)

CA1: Improve outcomes in population health and healthcare	✓
CA2: tackle inequalities in outcomes, experience and access	✓
CA3: Enhance productivity and value for money	✓
CA4: Help the NHS support broader social and economic development	✓

Relevant legal/statutory issues

Note any relevant Acts, regulations, national guidelines etc

Any potential/actual conflicts of interest associated with the paper? (please tick)	Yes		No		N/A	✓
---	-----	--	----	--	-----	---

If yes, please specify

Equality analysis completed (please tick)	Yes		No		N/A	✓
---	-----	--	----	--	-----	---

Item: 9.2.3

If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick)	Yes		No		N/A	✓
Key implications						
Are additional resources required?	As identified in confirmed minutes					
Has there been/does there need to be appropriate clinical involvement?	Yes, as part of Committee membership					
Has there been/does there need to be any patient and public involvement?	N/A					
Has there been/does there need to be partner and/or other stakeholder engagement?	N/A					